Trial Profile
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Onasemnogene-abeparvovec (Primary)
- Indications Spinal muscular atrophy
- Focus Registrational; Therapeutic Use
- Acronyms STR1VE EU
- Sponsors AveXis; Novartis Gene Therapies
- 13 Mar 2022 Results of post-hoc analysis from START, STR1VE-EU and STR1VE-US studies were presented at Novartis media release.
- 22 Jun 2021 Final results presented at the 7th Congress of the European Academy of Neurology
- 18 Jun 2021 According to a Novartis media release, data from this trial will be presented at the European Academy for Neurology (EAN) Virtual Congress 2021.